The WIRB-Copernicus Group announced it has formed a new cancer-focused institutional review board, WCG Oncology.
The WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for clinical research, announced it has formed a new cancer-focused institutional review board, WCG OncologyTM. WCG Oncology features its Expert Advisory Board, which provides strategic counsel to WCG regarding the changing oncology research landscape, covering cutting-edge theory, scientific methods, technologies, and study designs.
WCG is creating this group because it is a fast-evolving medical fields--featuring advances in gene therapy, targeted treatments, and companion diagnostics. In the past four years, WCG has reviewed more than 4,000 oncology protocols, which have substantially increased in complexity.
WCG Oncology is constituted by three dedicated IRB panels, which focus wholly on the ethical oversight of oncology research, and a cadre of expert oncological specialists to assist in the review of complex and scientifically-challenging research.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.